Biogen Stock: FDA Approves Alzheimer's Treatment, But Medicare … – Investor's Business Daily

BREAKING: Bulls Flex Muscles With First Rally Of 2023

Biogen (BIIB) stock jumped Friday after the Food and Drug Administration approved its second Alzheimer’s treatment, now called Leqembi.
The approval is on an accelerated basis, meaning it’s contingent upon further testing. Specifically, the FDA says Leqembi should be used in patients with mild forms of Alzheimer’s disease. It notes Biogen and partner Eisai (ESALY) tested the drug in one specific group, but didn’t test Leqembi in patients with earlier- or later-stage forms of Alzheimer’s disease than that group.
“Patients at an early stage of the disease and their caregivers can now consider a new treatment option with their doctors,” Biogen Chief Executive Christopher Viehbacher said in an emailed statement. “Our focus now is on the path forward, working alongside Eisai with the goal of making Leqembi available to patients who may benefit from this treatment as soon as possible.”
On today’s stock market, Biogen stock rose 2.8% to close at 279.25. Eisai stock surged 4.1% and closed at 64.20.
Next up, the Centers for Medicare and Medicaid Services will make a decision on whether to reimburse patients for the cost of the Alzheimer’s treatment. This is critical for Biogen and Eisai.
Leqembi works by cutting down on built-up plaque in the brain known as beta amyloid. Over the course of 18 months, that led to a 27% slower decline in cognition for patients who received the Alzheimer’s treatment vs. the placebo recipients.
But Biogen and Eisai already gained accelerated approval for one Alzheimer’s drug, Aduhelm. Medicare officials said they hadn’t proved Aduhelm’s cognitive benefit in testing and declined to offer broad reimbursement. The question now is whether the agency will repeat that process with Leqembi. Leqembi’s benefit was clearer than Aduhelm’s in Phase 3 testing.
If reimbursed, analysts expect the Alzheimer’s treatment to be a major blockbuster. In a November report, RBC Capital Markets analyst Brian Abrahams said Leqembi could generate $400 million in worldwide sales in 2024, growing to $5 billion by 2027 and $10 billion by 2031.
That estimate allows some market split with Eli Lilly (LLY), which is also working on a beta amyloid-targeting drug, donanemab.
Biogen stock has traded higher with enthusiasm for the prospects of its Alzheimer’s treatment. Shares have a strong Relative Strength Rating of 91 out of a best-possible 99.
This means Biogen stock is in the top 9% of all stocks when it comes to 12-month performance, according to IBD Digital.
However, safety questions also plague Biogen and Lilly.
In Biogen’s study, 15% of patients had a genetic mutation in their APOE4 gene. This mutation makes them more susceptible to developing early-stage Alzheimer’s disease.
It also increases their risk of swelling in the brain in response to amyloid-targeting drugs. This group of APOE4 genetic mutation carriers also underperformed the placebo on a scale of Alzheimer’s symptoms.
Overall, about 17% of patients who received Leqembi experienced swelling or bleeding in the brain. In comparison, the side effect occurred in 9% of placebo recipients. The label for Leqembi warns against ARIA, noting it “usually does not have symptoms” but serious and life-threatening events may rarely occur. The label also warns against infusion-related reactions.
Importantly, Biogen stock remains above its 200-day line, though it has fallen below its 50-day moving average in recent weeks, MarketSmith.com shows.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Why 2023 Could Be The Year For Biotech Stocks
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Novocure Skyrockets 69% After Pulling Off A Once-In-Six-Years Feat
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
Find The Best Long-Term Investments With IBD Long-Term Leaders
Biotech executives believe genetic medicine will play an integral role in drug development in the not-too-distant future. (© Chris Gash)
6:44 AM ET If there’s one biotech area to watch in 2023, it’s genetic medicine, like CRISPR. But other trends also point to…
6:44 AM ET If there’s one biotech area to watch in 2023, it’s…
Biotech executives believe genetic medicine will play an integral role in drug development in the not-too-distant future. (© Chris Gash)
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2023 Investor’s Business Daily, LLC. All rights reserved

source